iBio (IBIO) Shares Outstanding (2010 - 2026)
iBio (IBIO) posted quarterly Shares Outstanding (Entity) of $119.6 million for Q1 2026, up 1088.04% year-over-year from $10.1 million in Q1 2025, and up 20.65% quarter-over-quarter from $99.1 million in Q4 2025.
iBio (IBIO) Shares Outstanding (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Shares Outstanding (Entity) for 17 consecutive years, with $119.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 1088.04% year-over-year to $119.6 million; the TTM figure through Mar 2026 stood at $119.6 million (up 1088.04% YoY), while the FY2025 annual figure was $10.5 million, up 174.05% from the prior year.
- Shares Outstanding (Entity) advanced to $119.6 million in Q1 2026 per IBIO's latest filing, from $99.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $119.6 million in Q1 2026 and bottomed at $436332.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $19.1 million across 5 years, with a median of $3.7 million in 2024.
- On a YoY basis, Shares Outstanding (Entity) climbed as much as 101137.12% in 2022 and fell as far as 0.14% in 2022.
- iBio's Shares Outstanding (Entity) stood at $490350.0 in 2022, then soared by 278.51% to $1.9 million in 2023, then jumped by 393.97% to $9.2 million in 2024, then jumped by 981.29% to $99.1 million in 2025, then advanced by 20.65% to $119.6 million in 2026.
- Business Quant data shows IBIO's Shares Outstanding (Entity) at $119.6 million in Q1 2026, $99.1 million in Q4 2025, and $53.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | 119.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119.60 Mn |
| Dec 31, 2025 | 99.13 Mn |
| Sep 30, 2025 | 52.98 Mn |
| Jun 30, 2025 | 10.50 Mn |
| Mar 31, 2025 | 9.86 Mn |
| Dec 31, 2024 | 9.13 Mn |
| Sep 30, 2024 | 8.63 Mn |
| Jun 30, 2024 | 3.83 Mn |
| Mar 31, 2024 | 3.71 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 612,250.00 |
| Mar 31, 2023 | 659,200.00 |
| Dec 31, 2022 | 490,350.00 |
| Sep 30, 2022 | 442,100.00 |
| Jun 30, 2022 | 436,050.00 |
| Mar 31, 2022 | 436,192.00 |
| Dec 31, 2021 | 435,980.00 |
| Sep 30, 2021 | 435,752.00 |
| Jun 30, 2021 | 391,240.00 |